The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
In this study phlebotomy will be evaluated as a therapy for non-alcoholic fatty liver disease (NAFLD), a common and important cause of liver disease. Phlebotomy has been used for many years in the treatment of disorders of iron overload such as hemochromatosis, where it is well tolerated and improves symptoms and survival. There is some evidence that it is also effective in treating NAFLD. However, previous studies have not evaluated whether phlebotomy improves liver biopsy findings. We will measure the severity disease in NAFLD patients prior to phlebotomy therapy and again at the end of treatment. This will allow us to accurately determine the benefit of this therapy in these patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
London Health Sciences Centre
London, Ontario, Canada
Severity of liver disease
Time frame: 6 months after final treatment
Severity of metabolic disease
Time frame: 6 months after final treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.